Personalized medicine in multiple sclerosis: hope or reality?

A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy

(2012) Bengt Skoog et al.   BRAIN

Identifying autoantigens in demyelinating diseases

(2012) Tobias Derfuss et al.   CURRENT OPINION IN NEUROLOGY

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

(2012) Adam P. Gregory et al.   NATURE

Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis

(2012) Rajneesh Srivastava et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

(2011) Manuel Comabella et al.   Current Neurology and Neuroscience Reports

Prediction of long-term disability in multiple sclerosis

(2011) R Schlaeger et al.   Multiple Sclerosis Journal

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

(2011) Stephen Sawcer et al.   NATURE

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

(2011) A. K. Probstel et al.   NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children

(2010) PH Lalive et al.   Multiple Sclerosis Journal

Brainstem lesions in clinically isolated syndromes

(2010) M. Tintore et al.   NEUROLOGY

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

Neutralizing Antibodies to Interferon-β and other Immunological Treatments for Multiple Sclerosis

(2009) Florian Deisenhammer   CNS DRUGS

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

(2009) Philip L De Jager et al.   LANCET NEUROLOGY

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

Neurological autoimmunity targeting aquaporin-4

(2009) S.R. Hinson et al.   NEUROSCIENCE

Gray matter atrophy is related to long-term disability in multiple sclerosis

(2008) Leonora K. Fisniku et al.   ANNALS OF NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

MRI in multiple sclerosis: current status and future prospects

(2008) Rohit Bakshi et al.   LANCET NEUROLOGY